Efficacy

Efficacy of Ketas (Ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

Ibudilast, known commercially as Ketas, is a phosphodiesterase inhibitor that has been used primarily in Asia for the treatment of asthma and post-stroke complications. Its efficacy in Amyotrophic Lateral Sclerosis (ALS) is currently an area of research interest, as it is hypothesized to have neuroprotective effects that could potentially slow the progression of the disease. While ibudilast is not currently approved for the treatment of ALS in the United States or Europe, early-phase clinical trials have suggested that it may reduce the rate of progression of ALS, as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). However, larger, more definitive clinical trials are needed to fully establish the efficacy of ibudilast in the treatment of ALS.

It is important to note that the use of ibudilast for ALS is considered off-label, and its efficacy for this indication has not been approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA). Patients interested in ibudilast as a treatment option for ALS should consult with their healthcare provider and may need to consider participation in clinical trials to access the medication for this use.

Efficacy of Radicava ORS (Edaravone) in Amyotrophic Lateral Sclerosis (ALS)

Radicava ORS (edaravone) is an antioxidant medication that has been approved by the FDA for the treatment of ALS. The efficacy of edaravone in slowing the decline in physical function in ALS patients has been demonstrated in clinical trials. Specifically, a six-month placebo-controlled study showed that patients receiving edaravone experienced less functional loss as measured by the ALSFRS-R compared to those receiving a placebo. This led to its approval and use as a treatment option for ALS in the United States.

Edaravone is thought to work by scavenging free radicals, which are believed to contribute to the oxidative stress associated with the neurodegeneration in ALS. The introduction of Radicava ORS, an oral suspension formulation of edaravone, has provided an alternative to the intravenous form, potentially improving accessibility and ease of administration for patients. While the efficacy of Radicava ORS in ALS has been established, it is important for patients and caregivers to understand that the treatment is not a cure for ALS but may help in slowing the progression of the disease. Ongoing research continues to evaluate the long-term benefits and optimal use of edaravone in ALS management.